Skip to main content
SpringerLink
Log in

The effect of canakinumab treatment on growth parameters in children with familial Mediterranean fever

  • ORIGINAL ARTICLE
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Introduction/objectives

This study aimed to evaluate the effect of canakinumab on growth parameters in children with familial Mediterranean fever (FMF).

Method

We conducted a retrospective analysis of 946 pediatric FMF patients followed in our center, of whom 37 were treated with canakinumab for at least three doses. Patients were assessed for demographic, clinical, and genetic characteristics. Data of height and weight percentiles and Z scores were recorded before and after canakinumab treatment and compared.

Results

The study group comprised 37 FMF patients with treated canakinumab. The median age (IQR) at diagnosis and canakinumab initiation was 3.0 (2.0–4.3) years and 7.0 (3.6–10.1) years, respectively. The median weight scores and mean body mass index (BMI) values significantly increased after canakinumab treatment. There was no change in height scores following canakinumab treatment.

Conclusion

Canakinumab treatment has improved off body weight and BMI parameters of FMF patients by controlling disease activity and inflammation.

Key Points

• To our knowledge, few studies in the literature evaluate the growth parameters of canakinumab treatment in FMF children.

• Canakinumab treatment has been shown to affect body weight and BMI positively.

• Long-term studies are needed for its effects on height.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

Not applicable.

References

  1. Sönmez HE, Batu ED, Özen S (2016) Familial Mediterranean fever: current perspectives. J Inflamm Res 17:13–20. https://doi.org/10.2147/JIR.S91352

    Article  Google Scholar 

  2. Chae JJ, Cho YH, Lee GS, Cheng J, Liu PP, Feigenbaum L et al (2011) Gain-of-function pyrin mutations induce NLRP3 protein-independent interleukin-1β activation and severe autoinflammation in mice. Immunity 34:755–768. https://doi.org/10.1016/j.immuni.2011.02.020

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. Akpolat T, Özkaya O, Özen S (2012) Homozygous M694V as a risk factor for amyloidosis in Turkish FMF patients. Gene 492:285–289. https://doi.org/10.1016/j.gene.2011.10.012

    Article  PubMed  CAS  Google Scholar 

  4. Özen S, Sag E, Ben-Chetrit E, Gattorno M, Gül A, Hashkes PJ, Kone-Paut I, Lachmann HJ, Tsitsami E, Twilt M, Benedetti F, Kuemmerle-Deschner JB (2021) Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach. Rheumatology (Oxford) 60:3799–3808. https://doi.org/10.1093/rheumatology/keaa863

    Article  PubMed  CAS  Google Scholar 

  5. Dinarello CA, Wolfe SM, Goldfinger SE, Dale DC, Alling DW (1974) Colchicine therapy for familial Mediterranean fever. N Engl J Med 291:934–937. https://doi.org/10.1056/NEJM197410312911804

    Article  PubMed  CAS  Google Scholar 

  6. Kallinich T, Haffner D, Niehues T, Huss K, Lainka E, Neudorf U et al (2007) Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics 119:e474–e483. https://doi.org/10.1542/peds.2006-1434

    Article  PubMed  Google Scholar 

  7. van der Hilst JCH, Moutschen M, Messiaen PE, Lauwerys BR, Vanderschueren S (2016) Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature. Biologics 10:75–80. https://doi.org/10.2147/BTT.S102954

    Article  PubMed  PubMed Central  Google Scholar 

  8. Hentgen V, Vinit C, Fayand A, Georgin-Lavialle S (2020) The use of interleukine-1 inhibitors in familial Mediterranean fever patients: a narrative review. Front Immunol 11:971. https://doi.org/10.3389/fimmu.2020.00971

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Yalçinkaya F, Ozen S, Ozçakar ZB, Aktay N, Cakar N, Düzova A et al (2009) A new set of criteria for the diagnosis of Clin Rheumatol familial Mediterranean fever in childhood. Rheumatology (Oxford) 48:395–398. https://doi.org/10.1093/rheumatology/ken509

    Article  PubMed  Google Scholar 

  10. Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G et al (2016) EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis 75:644–651. https://doi.org/10.1136/annrheumdis-2015-208690

    Article  PubMed  CAS  Google Scholar 

  11. Neyzi O, Bundak R, Gökçay G, Günöz H, Furman A, Darendeliler F et al (2015) Reference values for weight, height, head circumference, and body mass index in Turkish children. J Clin Res Pediatr Endocrinol 7:280–293. https://doi.org/10.4274/jcrpe.2183

    Article  PubMed  PubMed Central  Google Scholar 

  12. Zemer D, Livneh A, Danon YL, Pras M, Sohar E (1991) Long-term colchicine treatment in children with familial Mediterranean fever. Arthritis Rheum 34:973–977. https://doi.org/10.1002/art.1780340806

    Article  PubMed  CAS  Google Scholar 

  13. Başaran Ö, Uncu N, Çelikel BA, Taktak A, Gür G, Cakar N (2015) Interleukin-1 targeting treatment in familial Mediterranean fever: an experience of pediatric patients. Mod Rheumatol 25:621–624. https://doi.org/10.3109/14397595.2014.987437

    Article  PubMed  CAS  Google Scholar 

  14. Barut K, Sahin S, Adrovic A, Sinoplu AB, Yucel G, Pamuk G, Aydın AK, Dasdemir S, Turanlı ET, Buyru N, Kasapcopur O (2018) Familial Mediterranean fever in childhood: a single-center experience. Rheumatol Int 38:67–74. https://doi.org/10.1007/s00296-017-3796-0

    Article  PubMed  CAS  Google Scholar 

  15. Kucuksahin O, Yildizgoren MT, Ilgen U, Ates A, Kinikli G, Turgay M, Erten S (2017) Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever. Mod Rheumatol 27:350–355. https://doi.org/10.1080/14397595.2016.1194510

    Article  PubMed  CAS  Google Scholar 

  16. Yücel BB, Aydog O, Nalcacioglu H, Yılmaz (2021) Effectiveness of canakinumab treatment in colchicine resistant familial Mediterranean fever cases. Front Pediatr 9:710501. https://doi.org/10.3389/fped.2021.710501

    Article  PubMed  PubMed Central  Google Scholar 

  17. Yazılıtaş F, Aydoğ Ö, Özlü SG, Çakıcı EK, Güngör T, Eroğlu FK, Gür G, Bülbül M (2018) Canakinumab treatment in children with familial Mediterranean fever: report from a single center. Rheumatol Int 38:879–885. https://doi.org/10.1007/s00296-018-3993-5

    Article  PubMed  CAS  Google Scholar 

  18. Sag E, Akal F, Atalay E, Akca UK, Demir S, Demirel D, Batu ED, Bilginer Y, Ozen S (2020) Anti-IL1 treatment in colchicine-resistant paediatric FMF patients: real life data from the HELIOS registry. Rheumatology (Oxford) 59:3324–3329. https://doi.org/10.1093/rheumatology/keaa121

    Article  PubMed  CAS  Google Scholar 

  19. Topaloglu R, Batu ED, Orhan D, Ozen S, Besbas N (2016) Anti-interleukin 1 treatment in secondary amyloidosis associated with autoinflammatory diseases. Pediatr Nephrol 31:633–640. https://doi.org/10.1007/s00467-015-3249-5

    Article  PubMed  Google Scholar 

  20. MacRae VE, Wong SC, Farquharson C, Ahmed SF (2006) Cytokine actions in growth disorders associated with pediatric chronic inflammatory diseases (review). Int J Mol Med 18:1011–1018. https://doi.org/10.3892/ijmm.18.6.1011

    Article  PubMed  CAS  Google Scholar 

  21. Sozeri B, Yilmaz E, Mir S, Berdeli A (2011) Effect of colchicine-resistant familial mediterranean fever on growth parameters. Arch Rheumatol 26:1–6

    Google Scholar 

  22. Türkmen M, Soylu OB, Kasap B, Güneş S, Tüfekçi O, Soylu A, Erçal D, Kavukçu S (2008) Growth in familial mediterranean fever: effect of attack rate, genotype and colchicine treatment. J Pediatr Endocrinol Metab 21:789–792. https://doi.org/10.1515/jpem.2008.21.8.789

    Article  PubMed  Google Scholar 

  23. Yoldaş TÇ, Çakar N, Başaran Ö, Acar B, Uncu N, Çaycı FŞ (2016) The effect of colchicine and disease severity on physical growth in children with familial Mediterranean fever. Clin Rheumatol 35:1603–1607. https://doi.org/10.1007/s10067-015-3077-9

    Article  PubMed  Google Scholar 

  24. Kişla Ekinci RM, Balci S, Akay E, Doğruel D, Altintaş DU, Yilmaz M (2019) Disease severity and genotype affect physical growth in children with familial Mediterranean fever. Arch Rheumatol 34:288–293. https://doi.org/10.5606/ArchRheumatol.2019.7198

    Article  PubMed  PubMed Central  Google Scholar 

  25. Pinchevski-Kadir S, Gerstein M, Pleniceanu O, Yacobi Y, Vivante A, Granat OE, Spielman S, Oz RS, Tirosh I (2023) Effect of interleukin-1 antagonist on growth of children with colchicine resistant or intolerant FMF. Pediatr Rheumatol Online J 21:4. https://doi.org/10.1186/s12969-022-00784-6

    Article  PubMed  PubMed Central  Google Scholar 

  26. Balci S, Ekinci RMK, Dogruel D, Altintas DU, Yilmaz M (2020) Growth parameters of Turkish children with an autoinflammatory disease before and after canakinumab treatment. Indian Pediatr 57:637–640. https://doi.org/10.1007/s13312-020-1892-9

    Article  PubMed  Google Scholar 

  27. Karabulut Y, Gezer HH, Duruöz MT (2022) Canakinumab is effective in patients with familial Mediterranean fever resistant and intolerant to the colchicine and/or anakinra treatment. Rheumatol Int 42:81–86. https://doi.org/10.1007/s00296-021-04997-y

    Article  PubMed  CAS  Google Scholar 

  28. Berdeli A, Şenol Ö, Talay G (2019) Treatment of familial mediterranean fever with canakinumab in patients who are unresponsive to colchicine. Eur J Rheumatol 6:85–88. https://doi.org/10.5152/eurjrheum.2019.18190

    Article  PubMed  PubMed Central  Google Scholar 

  29. Tomokawa T, Koga T, Endo Y, Michitsuji T, Kawakami A (2022) Efficacy and safety of canakinumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: a single-centre observational study. Mod Rheumatol 32:797–802. https://doi.org/10.1093/mr/roab048

    Article  PubMed  Google Scholar 

  30. Gülez N, Makay B, Sözeri B (2020) Long-term effectiveness and safety of canakinumab in pediatric familial Mediterranean fever patients. Mod Rheumatol 30:166–171. https://doi.org/10.1080/14397595.2018.1559488

    Article  PubMed  CAS  Google Scholar 

  31. Kacar M, Savic S, van der Hilst JCH (2020) The efficacy, safety and tolerability of canakinumab in the treatment of familial Mediterranean fever: a systematic review of the literature. J Inflamm Res 13:141–149. https://doi.org/10.2147/JIR.S206204

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatric Rheumatology, Ankara Etlik City Hospital, Ankara, Turkey

    Elif Arslanoglu Aydin, Esra Baglan, Nesibe Gokce Kocamaz, İlknur Bagrul, Serife Tuncez & Semanur Ozdel

Authors
  1. Elif Arslanoglu Aydin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Esra Baglan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nesibe Gokce Kocamaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. İlknur Bagrul
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Serife Tuncez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Semanur Ozdel
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Manuscript: EAA, SO; literature search: EAA, SO, EB; study design: EAA, SO, EB; data collection: EAA, IB, NGK, ST; data analysis: EA, SO; data interpretation: EAA, IB, NGK; writing: EAA, SO. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Elif Arslanoglu Aydin.

Ethics declarations

Ethics approval and consent to participate

The written consents from the patient families were obtained according to the Declaration of Helsinki (1964) and the study was approved by the ethics committee of Ankara City Hospital.

Disclosures

None.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aydin, E.A., Baglan, E., Kocamaz, N.G. et al. The effect of canakinumab treatment on growth parameters in children with familial Mediterranean fever. Clin Rheumatol 43, 387–392 (2024). https://doi.org/10.1007/s10067-023-06752-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-023-06752-z

Keywords

Search

Navigation